Literature DB >> 11306239

Natriuretic peptide signalling: molecular and cellular pathways to growth regulation.

M Silberbach1, C T Roberts.   

Abstract

The natriuretic peptides (NPs) constitute a family of polypeptide hormones that regulate mammalian blood volume and blood pressure. The ability of the NPs to modulate cardiac hypertrophy and cell proliferation as well is now beginning to be recognized. The NPs interact with three membrane-bound receptors, all of which contain a well-characterized extracellular ligand-binding domain. The R1 subclass of NP receptors (NPR-A and NPR-B) contains a C-terminal guanylyl cyclase domain and is responsible for most of the NPs downstream actions through their ability to generate cGMP. The R2 subclass lacks an obvious catalytic domain and functions primarily as a clearance receptor. This review focuses on the signal transduction pathways initiated by ligand binding and other factors that help to determine signalling specificities, including allosteric factors modulating cGMP generation, receptor desensitization, the activation and function of cGMP-dependent protein kinase (PKG), and identification of potential nuclear or cytoplasmic targets such as the mitogen-activated protein kinase signalling (MAPK) cascade. The inhibition of cardiac growth and hypertrophy may be an important but underappreciated action of the NP signalling system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306239     DOI: 10.1016/s0898-6568(01)00139-5

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  40 in total

1.  Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation.

Authors:  Kris A Steinbrecher; Steve A Wowk; Jeffrey A Rudolph; David P Witte; Mitchell B Cohen
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  A friend within the heart: natriuretic peptide receptor signaling.

Authors:  Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

3.  B Type natriuretic peptide: a good omen in myocardial ischaemia?

Authors:  S P D'Souza; G F Baxter
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

4.  B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts.

Authors:  Brenda K Huntley; Tomoko Ichiki; S Jeson Sangaralingham; Horng H Chen; John C Burnett
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

5.  ANP/NPRA signaling preferentially mediates Th2 responses in favor of pathological processes during the course of acute allergic asthma.

Authors:  Libing Ma; Jinrong Zeng; Biwen Mo; Changming Wang; Yabing Sun; Meng Zhang; Shaokun Liu; Xudong Xiang; Cong-Yi Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Cardioprotective actions of cyclic GMP: lessons from genetic animal models.

Authors:  Christian F Deschepper
Journal:  Hypertension       Date:  2009-12-14       Impact factor: 10.190

7.  NPR-B natriuretic peptide receptors in human corneal epithelium: mRNA, immunohistochemistochemical, protein, and biochemical pharmacology studies.

Authors:  Parvaneh Katoli; Najam A Sharif; Anupam Sule; Slobodan D Dimitrijevich
Journal:  Mol Vis       Date:  2010-07-07       Impact factor: 2.367

8.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06

9.  Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma.

Authors:  Xiaoqin Wang; Weidong Xu; Xiaoyuan Kong; Dongqing Chen; Gary Hellermann; Terry A Ahlert; Joseph D Giaimo; Stephania A Cormier; Xu Li; Richard F Lockey; Subhra Mohapatra; Shyam S Mohapatra
Journal:  Respir Res       Date:  2009-07-17

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.